Efficacy of Opicapone and Levodopa with Different Levodopa Daily Doses in Parkinson’s Disease Patients with Early Motor Fluctuations: Findings from the Korean ADOPTION Study
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus an additional levodopa (L-DOPA) dose of 100 mg in patients with Parkinson’s disease (PD)…Assessing a Video Based Approach at Measuring Parkinson’s Disease Severity – A Validation Study
Objective: To validate the Parkinson’s remote interactive monitoring system’s assessment of Parkinson’s disease compared to a clinical assessment completed by a movement disorder specialist. Background:…Remote recruitment of hyposmic participants identifies biomarkers related to neuronal alpha-synuclein disease
Objective: To evaluate the proportion of people with dopaminergic deficit and positive alpha-synuclein seed amplification assay (aSyn SAA) among a remotely identified group of hyposmic…Safety and tolerability of opicapone in Parkinson’s Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)
Objective: To compare the safety and tolerability of once-daily opicapone (OPC) 50mg as add-on to stable levodopa/dopa decarboxylase inhibitor (L-DOPA/DDCI) therapy in patients from early…Five-Year Changes in MDS-UPDRS-III after Light Treatment (Photobiomodulation)
Objective: To determine the effectiveness of photobiomodulation (light therapy) on MDS-UPDRS-III scores over a five-year period Background: As a progressive neurodegenerative disease, worsening of motor…Slow-SPEED-NL: study protocol for a remote trial of exercise for Parkinson’s disease prevention
Objective: To determine the feasibility and preliminary efficacy of a remote exercise intervention in prodromal Parkinson’s disease (PD). Background: Disease-slowing interventions have been ineffective in…Exidavnemab offers opportunities as a potential disease modifying therapy in several synucleinopathies
Objective: Immunotherapy against α-synuclein is a promising novel treatment strategy for Parkinson's disease and related α-synucleinopathies. We have developed exidavnemab (BAN0805), a monoclonal antibody with…Safety and Efficacy of Sublingual Apomorphine in Parkinson’s Patients with or without Concomitant Dopamine Agonists Use
Objective: This post-hoc analysis of Study CTH-301 aimed to assess the safety and efficacy of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease with…Using Algorithm Guided Programming to Treat Parkinson’s Disease Patients Implanted with Deep Brain Stimulation
Objective: To compare acute outcomes from Parkinson’s disease patients implanted with Deep Brain Stimulation (DBS) programmed using Algorithm Guided Programming (AGP) versus conventional, standard of…Gender Differences Following Bilateral STN DBS Surgery in Parkinson’s Disease
Objective: To examine DBS surgery outcomes within the Deep Brain Stimulation (DBS) PD cohort at the NIH among males and females and improve our understanding…
- « Previous Page
- 1
- …
- 83
- 84
- 85
- 86
- 87
- …
- 338
- Next Page »